Skip to main content

Table 1 Subject demographics and baseline characteristics

From: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Patient Characteristics

AboBoNT-A (N = 253)

OnaBoNT-A (N = 103)

All Patients (N = 356)

Age in Years

 18 to 30

13 (5.1%)

4 (3.9%)

17 (4.8%)

 31 to 40

37 (14.6%)

9 (8.7%)

46 (12.9%)

 41 to 50

74 (29.2%)

18 (17.5%)

92 (25.8%)

 51 to 60

58 (22.9%)

36 (35%)

94 (26.4%)

 61 to 70

45 (17.8%)

26 (25.2%)

71 (19.9%)

  > 70

26 (10.3%)

10 (9.7%)

36 (10.1%)

Body Weight (kg), mean (SD)

72.7 (14.9)

73.7 (15.3)

73.0 (15.0)

Sex (n,%)

 Female

162 (64%)

69 (67%)

231 (64.9%)

 Male

91 (36%)

34 (33%)

125 (35.1%)

Previous Surgery (n,%)

 No

248 (98%)

100 (97.1%)

348 (97.8%)

 Yes

5 (2%)

3 (2.9%)

8 (2.2%)

Prior Treatment with BoNT-A (n,%)

 No

49 (19.4%)

7 (6.8%)

56 (15.7%)

 Yes

204 (80.6%)

96 (93.2%)

300 (84.3%)

Tremor (n,%)

 Absent

142 (56.1%)

41 (39.8%)

183 (51.4%)

 Present

111 (43.9%)

62 (60.2%)

173 (48.6%)

Predominant Component (n,%)

 Not Rotation

49 (19.4%)

38 (36.9%)

87 (24.4%)

 Rotation

204 (80.6%)

65 (63.1%)

269 (75.6%)

EMG at Baseline (n,%)

 No

151 (59.7%)

40 (38.8%)

191 (53.7%)

 Yes

102 (40.3%)

63 (61.2%)

165 (46.3%)

TWSTRS Scores at Baseline

 Total Score, mean (SD)

37.8 (9.4)

33.9 (11.1)

37.1 (10.2)

 Severity Subscale Score, mean (SD)

20.1 (3.5)

18.9 (3.4)

19.8 (3.5)

 Disability Subscale Score, mean (SD)

11.1 (5.3)

9.2 (6.0)

10.7 (5.6)

 Pain Subscale Score, mean (SD)

6.6 (4.7)

5.8 (4.9)

6.6 (4.8)

EQ-5D Utility Score at Baseline, mean (SD)

0.56 (0.03)

0.57 (0.03)

0.57 (0.03)

Total Injected Units of BoNT-A, mean (SD)

598.8 (231.9)

172.9 (66.5)

  1. SD Standard deviation; EMG electromyography; BoNT-A Botulinum Neurotoxin type A; TWSTRS Toronto Western Spasmodic Torticollis Rating Scale; EQ-5D EuroQol 5 Dimensions Questionnaire